Zydus, Lupin ink pact to co-market diabetes drug

New Delhi: Zydus Lifesciences on Tuesday said it has entered into a licensing and supply agreement with Lupin to expand access of diabetes treatment drug Semaglutide Injection (15 mg/3 ml) with patient-friendly reusable pen device in India.

The pact aims to strengthen patient access for advanced diabetes and weight management therapies. As per the agreement, Lupin will have semi-exclusive rights to co-market Zydus' innovative Semaglutide Injection in the Indian market under brand names Semanext and Livarise.

Zydus will market the product under brand names Semaglyn, Mashema and and Altermet.